HOME
ABOUT
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
HOME
ABOUT
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
PURNOVATE
16382
page-template-default,page,page-id-16382,bridge-core-2.5.8,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-24.3,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.2,vc_responsive
PURNOVATE
Unlocking the power of adenosine for non-opioid pain, addiction, and other diseases. Selectivity, Potency, Stability, Solubility
Purines + Innovate = Purnovate
ACQUISITION ANNOUNCMENT – December 10, 2020
Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) announces [put actual text of press release title here]
Read the Announcement
